Abstract:Importance: Increasing levels of high-density lipoprotein (HDL) cholesterol through pharmacologic inhibition of cholesteryl ester transfer protein (CETP) is a potentially important strategy for prevention and treatment of cardiovascular disease (CVD).Objective: To use genetic variants in the CETP gene to assess potential risks and benefits of lifelong lower CETP activity on CVD and other outcomes.Design, Setting, and Participants: This prospective biobank study included 151 217 individuals aged 30 to 79 years who were enrolled from 5 urban and 5 rural areas of China from June 25, 2004, through July 15, 2008. All participants had baseline genotype data, 17 854 of whom had lipid measurements and 4657 of whom had lipoprotein particle measurements. Median follow-up of 9.2 years (interquartile range, 8.2-10.1 years) was completed January 1, 2016, through linkage to health insurance records and death and disease registries.Exposures: Five CETP variants, including an East Asian loss-of-function variant (rs2303790), combined in a genetic score weighted to associations with HDL cholesterol levels.Main Outcomes and Measures: Baseline levels of lipids and lipoprotein particles, cardiovascular risk factors, incidence of carotid plaque and predefined major vascular and nonvascular diseases, and a phenome-wide range of diseases.Results: Among the 151 217 individuals included in this study (58.4% women and 41.6% men), the mean (SD) age was 52.3 (10.9) years. Overall, the mean (SD) low-density lipoprotein (LDL) cholesterol level was 91 (27) mg/dL; HDL cholesterol level, 48 (12) mg/dL. CETP variants were strongly associated with higher concentrations of HDL cholesterol (eg, 6.1 [SE, 0.4] mg/dL per rs2303790-G allele; P = 9.4 × 10-47) but were not associated with lower LDL cholesterol levels. Within HDL particles, cholesterol esters were increased and triglycerides reduced, whereas within very low-density lipoprotein particles, cholesterol esters were reduced and triglycerides increased. When scaled to 10-mg/dL higher levels of HDL cholesterol, the CETP genetic score was not associated with occlusive CVD (18 550 events; odds ratio [OR], 0.98; 95% CI, 0.91-1.06), major coronary events (5767 events; OR, 1.08; 95% CI, 0.95-1.22), myocardial infarction (3118 events; OR, 1.14; 95% CI, 0.97-1.35), ischemic stroke (13 759 events; OR, 0.94; 95% CI, 0.86-1.02), intracerebral hemorrhage (6532 events; OR, 0.94; 95% CI, 0.83-1.06), or other vascular diseases or carotid plaque. Similarly, rs2303790 was not associated with any vascular diseases or plaque. No associations with nonvascular diseases were found other than an increased risk for eye diseases with rs2303790 (4090 events; OR, 1.43; 95% CI, 1.13-1.80; P = .003).Conclusions and Relevance: CETP variants were associated with altered HDL metabolism but did not lower LDL cholesterol levels and had no significant association with risk for CVD. These results suggest that in the absence of reduced LDL cholesterol levels, increasing HDL cholesterol levels by inhibition of CETP may not confer significant benefits for CVD.

Relationship between the polymorphisms in the cholesterol ester transfer protein gene and the effect of fluvastatin

Study on the Correlation Between CETP TaqIB,KCNE1 S38G and Enos T-786C Gene Polymorphisms for Predisposition and Non-Valvular Atrial Fibrillation

The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis.

[Effects of Cholesterol Ester Transfer Protein Taq1B Polymorphism on Response of Serum HDL-C to Dietary Factors in Hyperlipidemia Patients].

Associations of Two Common Polymorphisms in MTHFR Gene with Blood Lipids and Therapeutic Efficacy of Simvastatin.

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis

Association of Gene Polymorphism at Cholesterol Ester Transfer Protein Locus with Obesity and Response to Dietary Intervention in Obesity

CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T Are Determinants of Inter-Subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers.

Association of endothelial lipase gene Thr111Ile and Gly26Ser polymorphism with lipoprotein in patients with coronary heart disease

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

[Relationship Between Gene Polymorphism at CETP Locus and Hyperlipidemia in the Middle-Aged and the Elder].

Association Between Cholesteryl Ester Transfer Protein-Taqib Polymorphism and Coronary Heart Disease

Impact of LDLR Polymorphisms on Lipid Levels and Atorvastatin’s Efficacy in a Northern Chinese Adult Han Cohort with Dyslipidemia

Genetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, China

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults

VARIABILITY IN PLASMA LIPIDS BETWEEN INTENSIVE STATINS THERAPY AND CONVENTIONAL DOSE STATINS COMBINED WITH EZETIMIBE THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS DISEASE

A Novel CYP7A1 Polymorphism is Associated with the Low-Density Lipoprotein Cholesterol Response to Atorvastatin

The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients

Single Nucleotide Polymorphisms of Genes Associated with High Density Lipoprotein Metabolism in Chinese Population

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin